Ontology highlight
ABSTRACT:
SUBMITTER: Hess G
PROVIDER: S-EPMC7306311 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Hess Georg G Wagner Karola K Keller Ulrich U La Rosee Paul P Atta Johannes J Hübel Kai K Lerchenmueller Christian C Schoendube Daniel D Witzens-Harig Mathias M Ruckes Christian C Medler Christoph C van Oordt Christina C Klapper Wolfram W Theobald Matthias M Dreyling Martin M
HemaSphere 20200608 3
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m<sup>2</sup>, day 1 + 2) and Rituximab (375 mg/m<sup>2</sup>, day 1) with Temsirolimus in doses from 25 to 75 mg in phase I and 50 mg Temsirolimus in phase II, added on day 1, 8, 15 of a 28 days cycle. The primary endpo ...[more]